1. Volume 160, Issue 1, Pages 62-73 (January 2015)
Dopamine Controls Systemic Inflammation through Inhibition of NLRP3 Inflammasome 
Yiqing Yan, Wei Jiang, Lei Liu, Xiaqiong Wang, Chen Ding, Zhigang Tian, Rongbin Zhou 
Cell 
Volume 160, Issue 1, Pages (January 2015)
DOI: /j.cell
Copyright © 2015 Elsevier Inc. Terms and Conditions

2. Cell  , 62-73DOI: ( /j.cell )
Copyright © 2015 Elsevier Inc. Terms and Conditions

3. Figure 1 DA Inhibits NLRP3 Inflammasome Activation
(A) Immunoblot analysis of IL-1β and cleaved caspase-1 (p20) in culture supernatants (SN) of LPS-primed BMDMs treated for 3 hr with various doses (above lanes) of DA and then stimulated with nigericin, and immunoblot analysis of the precursors of IL-1β (pro-IL-1β) and caspase-1 (pro-caspase-1) in lysates of those cells (Input).
(B–D) ELISA of IL-1β (B), IL-18 (C), and TNF-α (D) in supernatants from LPS-primed BMDMs treated for 3 hr with various doses (above lanes) of DA and then stimulated with nigericin.
(E) Immunoblot analysis of IL-1β and cleaved caspase-1 (p20) in culture supernatants (SN) of LPS-primed BMDMs treated for 3 hr with DA and then stimulated with MSU, nigericin, ATP, and Alum, and immunoblot analysis of the precursors of IL-1β (pro-IL-1β) and caspase-1 (pro-caspase-1) in lysates of those cells (Input).
(F) ELISA of IL-1β in supernatants from LPS-primed BMDMs treated for 3 hr with DA and then stimulated with MSU, nigericin, ATP, and Alum.
Data are means ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p <
See also Figure S1.
Cell  , 62-73DOI: ( /j.cell )
Copyright © 2015 Elsevier Inc. Terms and Conditions

4. Figure 2 DA Inhibits NLRP3 Inflammasome Activation via DRD1
(A) ELISA of IL-1β in supernatants from LPS-primed BMDMs transfected with control siRNA with a scrambled sequence or Drd1-Drd5-specific siRNA as indicated, treated for 3 hr with DA and stimulated with nigericin.
(B) ELISA of IL-1β in supernatants from LPS-primed BMDMs of Drd1−/− and Drd2−/− mice treated for 3 hr with DA and stimulated with nigericin.
(C) Immunoblot analysis of IL-1β and cleaved caspase-1 (p20) in culture supernatants (SN) of LPS-primed BMDMs from Drd1−/− mice treated for 3 hr with DA and then stimulated with nigericin, and immunoblot analysis of the precursors of IL-1β (pro-IL-1β), caspase-1 (pro-caspase-1) and β-actin in lysates of those cells (Input).
(D) Immunoblot analysis of IL-1β and cleaved caspase-1 (p20) in culture supernatants (SN) of LPS-primed BMDMs treated for 3 hr with various doses (above lanes) of A and then stimulated with nigericin, and immunoblot analysis of the precursors of IL-1β (pro-IL-1β) and caspase-1 (pro-caspase-1) in lysates of those cells (Input).
(E) ELISA of IL-1β in supernatants from LPS-primed BMDMs of Drd1−/− and Drd2−/− mice treated for 3 hr with A and then stimulated with nigericin.
Data are means ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p <
See also Figure S2.
Cell  , 62-73DOI: ( /j.cell )
Copyright © 2015 Elsevier Inc. Terms and Conditions

5. Figure 3
DRD1 Signaling Promotes NLRP3 Ubiquitination and Degradation to Inhibit NLRP3 Inflammasome
(A) Immunoblot analysis of NLRP3, AIM2, NLRC4, ASC, Pro-caspase-1, and β-actin from LPS-primed BMDMs treated for 3 hr with various doses of DA.
(B) Immunoblot analysis of NLRP3, ASC, Pro-caspase-1, and β-actin from LPS-primed BMDMs treated for different time points of DA.
(C) Immunoblot analysis of NLRP3, ASC, Pro-caspase-1, and β-actin from LPS-primed BMDMs of Drd1−/− mice treated for 3 hr of DA.
(D) LPS primed-BMDMs were treated with DA (0.2 mM). Immunoblot analysis of K48-Ub and K63-Ub proteins in cell lysates immunoprecipitated with NLRP3 antibody.
(E) LPS primed-BMDMs from Drd1−/− mice were treated with DA (0.2 mM) for 1 hr. Immunoblot analysis of K48-Ub protein in cell lysates immunoprecipitated with NLRP3 antibody.
(F) Immunoblot analysis of NLRP3 and β-actin in cell lysates from LPS-primed BMDMs treated with different doses of 3-MA for 30 min and then stimulated with DA (0.2 mM) for 3 hr.
(G) Immunoblot analysis of NLRP3 and β-actin in cell lysates from LPS-primed BMDMs treated with different doses of MG132 for 30 min and then stimulated with DA (0.2 mM) for 3 hr.
(H) Immunoblot analysis of LC3 and β-actin in cell lysates from LPS-primed BMDMs treated for different time points of DA (0.2 mM).
(I) Immunoblot analysis of LC3 and β-actin in cell lysates from LPS-primed BMDMs of Drd1−/− mice treated with DA (0.2 mM) for 3 hr.
See also Figure S3.
Cell  , 62-73DOI: ( /j.cell )
Copyright © 2015 Elsevier Inc. Terms and Conditions

6. Figure 4
DRD1 Signaling Promotes NLRP3 Ubiquitination and Degradation via cAMP
(A) ELISA of IL-1β in supernatants from LPS-primed BMDMs treated for 3 hr with forskolin and then stimulated with nigericin.
(B) Immunoblot analysis of IL-1β and cleaved caspase-1 (p20) in culture supernatants (SN) of LPS-primed BMDMs treated for 3 hr with various doses (above lanes) of forskolin and then stimulated with nigericin, and immunoblot analysis of the precursors of IL-1β (pro-IL-1β) and caspase-1 (pro-caspase-1) in lysates of those cells (Input).
(C) Immunoblot analysis of NLRP3 and β-actin in cell lysates from LPS-primed BMDMs treated for different time points of forskolin (100 μM).
(D) ELISA of IL-1β in supernatants from LPS primed-BMDMs treated with different doses of KH7 for 30 min before 3 hr DA treatment and then stimulated with nigericin.
(E) Immunoblot analysis of IL-1β and cleaved caspase-1 (p20) in culture supernatants (SN) of LPS primed-BMDMs treated with KH7 (5 μM) for 30 min before 3 hr DA treatment and then stimulated with nigericin.
(F) Immunoblot analysis of NLRP3 and β-actin in cell lysates from LPS primed-BMDMs treated with different doses of KH7 for 30 min before 3 hr DA treatment.
(G) LPS primed-BMDMs were treated with KH7 (5 μM) for 30 min before 1 hr DA treatment. Immunoblot analysis of K48-Ub protein from the cell lysates immunoprecipitated with anti-NLRP3 antibody.
(H) Lysates from LPS primed-BMDMs were treated with different doses of cAMP for 30 min. Immunoblot analysis of K48-Ub protein from the cell lysates immunoprecipitated with anti-NLRP3 antibody.
(I) LPS primed-BMDMs were treated with DA (0.2 mM) for 1 hr. Immunoblot analysis of cAMP and NLRP3 proteins from the cell lysates immunoprecipitated with anti-NLRP3 antibody.
Data are means ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p <
See also Figure S4.
Cell  , 62-73DOI: ( /j.cell )
Copyright © 2015 Elsevier Inc. Terms and Conditions

7. Figure 5
DRD1 Signaling Promotes NLRP3 Ubiquitination through E3 Ligase MARCH7
(A) List of E3 ligase proteins for top peptide hits identified in mass spectrometry study.
(B) Immunoblot analysis of NLRP3 and β-actin in cell lysates from LPS-primed DA-treated BMDMs transfected with siRNA against March7.
(C) BMDMs were transfected with siRNA against March7. After 48 hr, the cells were primed with LPS and then stimulated with DA (0.2 mM) for 1 hr. Immunoblot analysis of K48-Ub protein from the cell lysates immunoprecipitated with anti-NLRP3 antibody.
(D) ELISA of IL-1β in supernatants from LPS-primed DA and nigericin-treated BMDMs transfected with siRNA against March7
(E) Flag-tagged NLRP3 constructs and MARCH7 construct were cotransfected in HEK293T cells. Immunoblot analysis of MARCH7 and Flag proteins in cell lysates immunoprecipitated with anti-Flag antibody. EV, empty vector.
(F) LPS primed-BMDMs were treated with KH7 (5 μM) for 30 min before 1 hr DA treatment. Immunoblot analysis of MARCH7 protein in cell lysates immunoprecipitated with anti-MARCH7 antibody.
(G and H) Flag-tagged NLRP3 construct and MARCH7 construct were cotransfected in HEK293T cells. Immunoblot analysis of K48-Ub protein in cell lysates immunoprecipitated with anti-Flag antibody.
Data are means ± SEM, ∗p < 0.05, ∗∗∗p <
See also Figure S5.
Cell  , 62-73DOI: ( /j.cell )
Copyright © 2015 Elsevier Inc. Terms and Conditions

8. Figure 6
DRD1 Signaling Prevents Neuroinflammation via Suppression of NLRP3 Inflammasome
(A) ELISA of IL-1β in supernatants from LPS-primed microglias of Drd1+/+ or Drd1−/− mice treated with DA (0.2 mM) for 3 hr and stimulated with nigericin.
(B) ELISA of IL-1β in supernatants from LPS-primed astrocytes of Drd1+/+ or Drd1−/− mice treated with DA (0.2 mM) for 3 hr and stimulated with nigericin.
(C) Immunoblot analysis of NLRP3 and β-actin in cell lysates from LPS-primed microglias of Drd1+/+ or Drd1−/− mice treated with DA (0.2 mM) for 3 hr.
(D) Immunoblot analysis of NLRP3 and β-actin in cell lysates from LPS-primed astrocytes of Drd1+/+ or Drd1−/− mice treated with DA (0.2 mM) for 3 hr.
(E) Immunofluorescent histochemical staining for tyrosine hydroxylase (TH) on the ventral mesencephalon of Drd1+/+ or Drd1−/− mice administrated with MPTP or MPTP plus A Scale bar represents 500 μM.
(F) Quantitative data of TH expression on the ventral mesencephalon of Drd1+/+ or Drd1−/− mice administrated with MPTP or MPTP plus A
(G) ELISA of IL-1β and IL-18 in serum of Drd1+/+ or Drd1−/− mice administrated with MPTP or MPTP plus A
(H) Immunoblot analysis of caspase-1 cleavage (p20), pro-caspase-1, and β-actin of Drd1+/+ or Drd1−/− mice administrated with MPTP or MPTP plus A
(I) Drd1+/+ and Drd1−/− mice were treated with MPTP. Immunoblot analysis of the lysates of brain tissue immunoprecipitated with anti-NLRP3 antibody.
Data are means ± SEM, ∗∗p < 0.01, ∗∗∗p <
See also Figure S6.
Cell  , 62-73DOI: ( /j.cell )
Copyright © 2015 Elsevier Inc. Terms and Conditions

9. Figure 7
DRD1 Signaling Prevents LPS-Induced Systemic Inflammation and MSU-Induced Peritoneal Inflammation via Suppression of NLRP3 Inflammasome
(A–C) ELISA of IL-1β (A), IL-18 (B), and TNF-α (C) in serum of Nlrp3+/+ or Nlrp3−/− mice intraperitoneally injected with LPS (20 mg/kg of body weight) with or without DA (50 mg/kg of body weight).
(D–F) ELISA of IL-1β (D), IL-18 (E), and TNF-α (F) in serum of Drd1+/+ or Drd1−/− mice intraperitoneally injected with LPS (20 mg/kg of body weight) with or without DA (50 mg/kg of body weight).
(G and H) ELISA of IL-1β (G) and IL-18 (H) in serum of Nlrp3−/− mice or Nlrp3−/−Drd1−/− mice intraperitoneally injected with LPS (20 mg/kg of body weight).
Data are means ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < NS p > 0.05.
See also Figure S7.
Cell  , 62-73DOI: ( /j.cell )
Copyright © 2015 Elsevier Inc. Terms and Conditions

10. Figure S1
The Effect of DA Treatment on Inflammasome Activation, Related to Figure 1
(A and B) ELISA of IL-1β (A) and IL-18 (B) in supernatants from LPS primed-BMDMs of Nlrp3+/+ or Nlrp3−/− mice treated with DA (0.2 mM) for 3 hr and stimulated with nigericin.
(C) ELISA of IL-1β in supernatants from LPS primed-BMDMs treated with DA one time at the dose of 1.5, 3, 45, or 90 μM, or thirty times (time interval is 5 min) at dose of 1.5 or 3 mM (labeled as 30X1.5 or 30X3) and stimulated with nigericin.
(D) ELISA of IL-1β in supernatants from LPS primed-BMDMs pretreated with Phenelzine (PLZ, 10 μM) plus 3,5-Dinitrocatechol (DNC, 10 μM), treated with different dose of DA for 3 hr and stimulated with nigericin.
(E) LDH release assay in supernatants from LPS-primed BMDMs stimulated with different doses of DA for 9 hr.
(F) Immunoblot analysis of IL-1β and cleaved caspase-1 (p20) in culture supernatants (SN) of LPS-primed BMDMs treated for 3 hr with DA and then stimulated with MSU or poly (dA:dT), and immunoblot analysis of the precursors of IL-1β (pro-IL-1β) and caspase-1 (pro-caspase-1) in lysates of those cells (Input).
(G) ELISA of IL-1β in supernatants from LPS-primed BMDMs treated for 3 hr with DA and then stimulated with MSU or poly (dA:dT).
(H) Immunoblot analysis of IL-1β and cleaved caspase-1 (p20) in culture supernatants (SN) of LPS-primed BMDMs treated for 3 hr with DA and then stimulated with MSU or Salmonella, and immunoblot analysis of the precursors of IL-1β (pro-IL-1β) and caspase-1 (pro-caspase-1) in lysates of those cells (Input).
(I) ELISA of IL-1β in supernatants from LPS-primed BMDMs treated for 3 hr with DA and then stimulated with MSU or Salmonella.
Data are means ± SEM, ∗∗∗p <
Cell  , 62-73DOI: ( /j.cell )
Copyright © 2015 Elsevier Inc. Terms and Conditions

11. Figure S2 Role of DRDs in Inflammasome Inhibition, Related to Figure 2
(A) Immunoblot analysis of Drd1, Drd2, Drd5 and β-actin from BMDMs transfected with siRNA against Drd1, Drd2 and Drd5 as indicated
(B) Q-PCR analysis of Drd3 and Drd4 from BMDMs transfected with siRNA against Drd3 and Drd4 as indicated
(C) LDH release assay in supernatant from LPS-primed BMDMs stimulated with different doses of A for 9 hr.
(D) Immunoblot analysis of IL-1β and cleaved caspase-1 (p20) in culture supernatants (SN) of LPS primed-BMDMs treated with DA (0.2 mM), Quinelorane, Propylamine and PD for 3 hr and stimulated with nigericin. and immunoblot analysis of the precursors of IL-1β (pro-IL-1β) and caspase-1 (pro-caspase-1) in lysates of those cells (Input).
(E) ELISA of TNF-α in supernatants from BMDMs of Drd1−/− and Drd2−/− mice treated with different doses of DA and stimulated with ultra-LPS (500 ng/ml) for 6 hr.
Cell  , 62-73DOI: ( /j.cell )
Copyright © 2015 Elsevier Inc. Terms and Conditions

12. Figure S3
DRD1 Signaling Promotes NLRP3 Degradation, Related to Figure 3
(A) Immunoblot analysis of NLRP3, ASC, Pro-caspase-1 and β-actin from LPS-primed BMDMs treated for 3 hr with various doses of A
(B) Immunoblot analysis of NLRP3, ASC, Pro-caspase-1 and β-actin from LPS-primed BMDMs treated for different time points of A
(C) Confocal microscopy analysis of HEK293T cells transfected with EGFP-NLRP3 and treated with DA for 1 hr. Scale bar, 20 μM.
(D) ELISA of IL-1β in supernatants from LPS primed-BMDMs pretreated with 3-MA for 30 min, treated with DA for 3 hr and stimulated with nigericin.
Data are means ± SEM, ∗∗∗p <
Cell  , 62-73DOI: ( /j.cell )
Copyright © 2015 Elsevier Inc. Terms and Conditions

13. Figure S4
Role of cAMP in DA-Induced NLRP3 Ubiquitination and Degradation, Related to Figure 4
(A) LPS primed-BMDMs were treated with forskolin (100 μM) for 1 hr. Immunoblot analysis of K48-Ub protein from the cell lysates immunoprecipitated with anti-NLRP3 antibody.
(B) Immunoblot analysis of IL-1β in culture supernatants of LPS-primed BMDMs treated with different doses of H89 before 3 hr DA treatment, and stimulated with nigericin, and immunoblot analysis of the precursors of IL-1β (pro-IL-1β) in lysates of those cells.
(C) Immunoblot analysis of NLRP3 and β-actin in cell lysates from LPS-primed BMDMs treated with different doses of H89 before 3 hr DA treatment.
(D) ELISA of IL-1β in supernatants from LPS primed-BMDMs treated with different doses of 8-pCPT-2′-O-Me-cAMP for 3 hr and stimulated with nigericin.
(E) Immunoblot analysis of NLRP3 and β-actin in cell lysates from LPS-primed BMDMs treated with different doses of 8-pCPT-2′-O-Me-cAMP for 3 hr.
(F) Immunoblot analysis of LC3 and β-actin in cell lysates from LPS-primed BMDMs treated with KH7 (5 μM) for 30 min before 3 hr DA treatment.
(G) Immunoblot analysis of LC3 and β-actin in cell lysates from LPS-primed BMDMs treated with forskolin (100 μM) for 3 hr.
(H) Immunoblot analysis of LC3 and β-actin in cell lysates from LPS-primed BMDMs treated with 8-pCPT-2′-O-Me-cAMP (100 μM) for 3 hr.
(I) Immunoblot analysis of LC3 and β-actin in cell lysates from LPS-primed BMDMstreated with H89 (40 μM) before 3 hr DA treatment.
(J) Confocal microscopy analysis of HEK293T cells transfected with EGFP-NLRP3 and treated with KH7 (5 μM) for 30 min followed by 1 hr DA treatment. Scale bar, 20 μM.
Cell  , 62-73DOI: ( /j.cell )
Copyright © 2015 Elsevier Inc. Terms and Conditions

14. Figure S5
Role of MARCH7 in DA-Induced NLRP3 Inflammasome Inhibition, Related to Figure 5
(A) Immunoblot analysis of Chip, Ubr5, March7 and β-actin from BMDMs transfected with siRNA against Chip, Ubr5 and March7 as indicated
(B) Immunoblot analysis of NLRP3 and β-actin in cell lysates from LPS-primed and DA-treated BMDMs transfected with siRNA against Chip.
(C) Immunoblot analysis of NLRP3 and β-actin in cell lysates from LPS-primed and DA-treated BMDMs transfected with siRNA against Ubr5.
(D) Immunoblot analysis of NLRP3 and β-actin in cell lysates from LPS-primed and forskolin-treated BMDMs transfected with siRNA against March7
(E) BMDMs were transfected with siRNA against March7, after 48 hr, the cells were primed with LPS and then stimulated with forskolin (100 μM) for 1 hr. Immunoblot analysis of K48-Ub protein in cell lysates immunoprecipitated with NLRP3 antibody.
(F) ELISA of IL-1β in supernatants from BMDMs transfected with siRNA against March7, primed with LPS, stimulated with forskolin (100 μM) for 3 hr and treated with nigericin.
Data are means ± SEM, ∗∗p < 0.01, ∗∗∗p <
Cell  , 62-73DOI: ( /j.cell )
Copyright © 2015 Elsevier Inc. Terms and Conditions

15. Figure S6
NLRP3 Inflammasome Plays a Critical Role in MPTP-Induced Neuroinflammation, Related to Figure 6
(A) Immunofluorescent histochemical staining for tyrosine hydroxylase (TH) on the ventral mesencephalon of Nlrp3+/+ mice, Nlrp3−/− mice or Nlrp3−/−Drd1−/− mice administrated with either saline or MPTP. Scale bar, 500 μM.
(B) Quantitative data of TH expression on the ventral mesencephalon of Nlrp3+/+ mice, Nlrp3−/− mice or Nlrp3−/−Drd1−/− mice administrated with either saline or MPTP.
(C) ELISA of IL-1β and IL-18 in serum of Nlrp3+/+ mice, Nlrp3−/− mice or Nlrp3−/−Drd1−/− mice administrated with either saline or MPTP.
(D) Immunoblot analysis of caspase-1 cleavage (p20), pro-caspase-1 and β-actin of Nlrp3+/+ mice, Nlrp3−/− mice or Nlrp3−/−Drd1−/− mice administrated with either saline or MPTP.
Data are means ± SEM, ∗∗p < 0.01, ∗∗∗p < 0001, NS p > 0.05.
Cell  , 62-73DOI: ( /j.cell )
Copyright © 2015 Elsevier Inc. Terms and Conditions

16. Figure S7
DRD1 Signaling Promotes NLRP3 Ubiquitination and Prevents LPS-Induced Septic Shock In Vivo, Related to Figure 7
(A) Drd1+/+ or Drd1−/− mice were intraperitoneally injected with LPS (20mg/kg of body weight) and DA (50 mg/kg of body weight) for 2 hr,. Immunoblot analysis of K48-Ub protein in cell lysates of peritoneal macrophages immunoprecipitated with anti-NLRP3 antibody.
(B) Immunoblot analysis of NLRP3 and β-actin in cell lysates of peritoneal macrophages from Drd1+/+ or Drd1−/− mice intraperitoneally injected with LPS (20mg/kg of body weight) and DA (50 mg/kg of body weight) for 4 hr.
(C) ELISA of IL-1β in serum of Wild-type mice preconditioned by daily intraperitoneally injection of 3-MA (10 mg/kg) for 4 consecutive days prior to LPS (20mg/kg of body weight) and DA (50 mg/kg of body weight) treatment.
(D) ELISA of IL-1β in the peritoneal cavity of Drd1+/+ or Drd1−/− mice intraperitoneally injected with MSU (1 mg/mouse) with or without DA (50 mg/kg of body weight)
(E) FACS analysis of neutrophil numbers in the peritoneal cavity of Drd1+/+ or Drd1−/− mice intraperitoneally injected with MSU (1 mg/mouse) with or without DA (50 mg/kg of body weight)
Data are means ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < NS p > 0.05.
Cell  , 62-73DOI: ( /j.cell )
Copyright © 2015 Elsevier Inc. Terms and Conditions